Dyne Therapeutics (DYN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Dyne Therapeutics (DYN) is Neutral.

The composite score behind that read is -0.06, weighing +0.39 of bullish evidence against -0.24 bearish.

Dyne Therapeutics last closed at $16.64, +1.65% on the session.

Against the IVW growth benchmark the position is +0.85% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

1 graded prediction for DYN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Dyne Therapeutics in the 15th percentile on return on equity, where 100 is best.

Dyne Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $3.06B.

StockMap tracks Dyne Therapeutics as the 69th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Dyne Therapeutics ranks 155th of 381 in the group, against a group median of -0.08.